Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer

NCT ID NCT06843447

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload directly to them. The trial will check safety and how well the drug shrinks tumors, given alone or with other anticancer agents.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Raludotatug deruxtecan (R-DXd), an antibody-drug conjugate that targets a protein on cancer cells and delivers a chemotherapy-like payload directly to them.
What this could lead to
If this trial succeeds, it could offer a new treatment option for people with relapsed high-grade serous ovarian cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so results may not apply to everyone. The drug may cause side effects like low blood counts or liver issues, and it might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER RECURRENT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Barts Health NHS Trust ( Site 0401)

    RECRUITING

    London, London, City of, E1 1RD, United Kingdom

  • Centre Hospitalier de l'Université de Montréal ( Site 0102)

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • Clinica Universidad de Navarra ( Site 0301)

    RECRUITING

    Madrid, Madrid, Comunidad de, 28027, Spain

  • Dana-Farber Cancer Institute ( Site 0015)

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Guy s & St Thomas NHS Foundation Trust ( Site 0400)

    RECRUITING

    London, London, City of, SE1 3SS, United Kingdom

  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)

    RECRUITING

    Majadhonda, Madrid, 28222, Spain

  • Hospital General Universitario de Valencia ( Site 0305)

    RECRUITING

    Valencia, Valenciana, Comunitat, 46014, Spain

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre ( Site 0304)

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitario Virgen de la Victoria ( Site 0306)

    RECRUITING

    Málaga, 29010, Spain

  • Houston Methodist Hospital ( Site 0010)

    COMPLETED

    Houston, Texas, 77030, United States

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • McGill University Health Centre ( Site 0100)

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Memorial Sloan Kettering Cancer Center ( Site 0003)

    RECRUITING

    New York, New York, 10065, United States

  • OU Health University of Oklahoma Medical Center ( Site 7000)

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Rabin Medical Center ( Site 0203)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0202)

    RECRUITING

    Haifa, 3109601, Israel

  • Royal Marsden Hospital ( Site 0402)

    RECRUITING

    Fulham, England, SW3 6JJ, United Kingdom

  • START Mountain Region ( Site 0008)

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Shaare Zedek Medical Center ( Site 0201)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0200)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • TRIALS 365 ( Site 0020)

    RECRUITING

    Shreveport, Louisiana, 71103, United States

  • Texas Oncology - DFW ( Site 8000)

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • The Christie NHS Foundation Trust ( Site 0405)

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Foundation Trust. ( Site 0403)

    RECRUITING

    Sutton, England, SM2 5PT, United Kingdom

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • University Hospitals Sussex NHS Foundation Trust ( Site 0404)

    RECRUITING

    Brighton, East Sussex, BN2 1ES, United Kingdom

  • University of Virginia Health System ( Site 0011)

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.